Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-09-10, Stock:LLY, The news for the past five days is as follows:
2019-09-03: NEWS1: The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie.NEWS2: The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie.NEWS3: 5 Cancer-Fighting Stocks to Add to Your Portfolio.NEWS4: 5 Cancer-Fighting Stocks to Add to Your Portfolio.NEWS5: The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie.NEWS6: 5 Cancer-Fighting Stocks to Add to Your Portfolio.
2019-09-04: NEWS1: Lilly to Participate in Morgan Stanley Global Healthcare Conference.NEWS2: Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M.NEWS3: Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M.NEWS4: Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M.
2019-09-05: NEWS1: AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC.NEWS2: AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC.NEWS3: Notable Thursday Option Activity: BLK, LLY, ABMD.NEWS4: Notable Thursday Option Activity: BLK, LLY, ABMD.NEWS5: Lilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program.NEWS6: Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?.NEWS7: Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?.NEWS8: AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC.NEWS9: J&J's Stelara Gets Approval in EU for Ulcerative Colitis.NEWS10: J&J's Stelara Gets Approval in EU for Ulcerative Colitis.NEWS11: J&J's Stelara Gets Approval in EU for Ulcerative Colitis.NEWS12: Calculating The Fair Value Of Eli Lilly and Company (NYSE:LLY).
2019-09-06: NEWS1: UPDATE 1-Novo Nordisk to cut insulin prices in the U.S..NEWS2: Novo Nordisk to cut insulin prices for some U.S. diabetics.NEWS3: Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'.NEWS4: INSIGHT-Inside drugmakers' strategy to boost cancer medicines with &quot;Lazarus effect&quot;.NEWS5: 4 Biotech Stocks With Big Catalysts in September.
2019-09-09: NEWS1: Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study.NEWS2: Novartis Announces Positive Long-Term Data on Migraine Drug.NEWS3: [video]Eli Lilly's Must-Hold Level on Drug-Data Pullback.NEWS4: Eli Lilly Stock Shrugs Off Upbeat Drug Data.NEWS5: Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial.NEWS6: Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer.NEWS7: Lilly's targeted RET drug shrinks tumors in lung cancer trial.

Answer: Rise